Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 15/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 15/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7649091 | 0.88 | PPARG (0.53) | BCL2L1MCL1FLT1FLT4KDR | |
| SCHEMBL6306639 | 0.83 | SLC22A12 (0.45) | BCL2L1MCL1FLT1FLT4KDR | |
| SCHEMBL5882017 | 0.82 | CCR2 (0.48) | FLT1FLT4KDRPPARGHDAC1 | |
| SCHEMBL7652979 | 0.79 | PPARG (0.53) | PPARGHDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL7652972 | 0.79 | PPARG (0.53) | PPARGHDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL6299641 | 0.79 | ALDH1A1 (0.39) | BCL2L1MCL1FLT1FLT4KDR | |
| SCHEMBL6135129 | 0.79 | PPARG (0.56) | BCL2L1MCL1FLT1FLT4KDR | |
| SCHEMBL6298902 | 0.78 | ALDH1A1 (0.38) | BCL2L1MCL1FLT1FLT4KDR | |
| SCHEMBL6299626 | 0.78 | FLT1 (0.37) | BCL2L1MCL1FLT1FLT4KDR | |
| SCHEMBL7650293 | 0.77 | PPARG (0.65) | FLT1FLT4KDRPPARGHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6420409-B1 | GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |